F COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2019
Lease description		The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028
Non current assets		$ 1,700,000		$ 1,700,000
Clinical service trial		12,000,000
Cash paid related to finance leases		500,000	$ 500,000
Cash paid related to finance leases interest		300,000	300,000
Cash paid related to operating leases		$ 48,000	66,000
Weighted average discount rate		8.80%
Maturity years		7 years 9 months 18 days
Finance lease right of use assets		$ 13,400,000		13,800,000
Operating lease - liability		1,200,000		1,300,000
Operating lease liabilities current		200,000		100,000
Net book value operating lease right of use assets		1,200,000		1,200,000
Operating lease expense		66,000	68,000
Finance lease liability		12,500,000		12,700,000
Research and development expenses		34,000,000.0
Sublease rental income			18,000
Finance lease obligations, net of current portion		1,000,000.0		$ 900,000
Lease Agreement [Member]
Estimated cost	$ 10,500,000
Cost to improve the maufacturing facility	6,700,000
Increased lease payments	2,400,000
Ergomed [Member]
Research and development expenses		600,000	$ 900,000
Net of discount		$ 11,300,000
Landlord [Member]
Facility improvement costs	2,400,000
Cost incurred, initial	$ 8,100,000